Human Molecular Genetics Advance Access originally published online on April 13, 2005
Human Molecular Genetics 2005 14(10):1393-1404; doi:10.1093/hmg/ddi148
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press.
SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism
Molecular Neurobiology Branch, IRP, NIDA, NIH, DHHS, Baltimore, MD 21224, USA
* To whom correspondence should be addressed at: Molecular Neurobiology Branch, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA. Tel: +1 4105502843; Fax: +1 4105501535; Email: zlin{at}intra.nida.nih.gov
Received February 7, 2005; Accepted April 4, 2005
The vesicular monoamine transporter 2 (VMAT2, SLC18A2) takes up cytosolic monoamines into intracellular secretory vesicles, preventing their neurotoxicity in the cytosol and discharging them into extracellular space by exocytosis. It has been shown that one-copy deletion of the VMAT2 gene increases locomotion activity significantly in response to drug treatments and dopamine neuron death rate in response to neurotoxin treatments in knockout mice. Little is known about promoter polymorphisms and their influence on SLC18A2 promoter activity. We have re-sequenced a 17.4 kb DNA in the SLC18A2 promoter region for Caucasians and revealed 47 polymorphisms that confer 13 haplotypes. One of the haplotypes reaches a frequency as high as 65%, likely due to positive selection. In vitro analysis showed a 20% difference in promoter activity between two frequent haplotypes and identified some of the polymorphisms that influence promoter activity. Four haplotype-defining single nucleotide polymorphisms (hdSNPs) can define the frequent haplotypes and by genotyping these hdSNPs, we find that haplotypes with 14234G and 2504C of SLC18A2 promoter region represent a protective factor against alcoholism (P=0.0038 by Fisher's exact tests). Therefore, SLC18A2 promoter haplotypes defined here create a foundation for transcriptional characterization of individuality and for association study on monoamine-related human diseases.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. A. Silveira Experimenting with Spirituality: Analyzing The God Gene in a Nonmajors Laboratory Course CBE Life Sci Educ, March 1, 2008; 7(1): 132 - 145. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fukui, R. M. Rodriguiz, J. Zhou, S. X. Jiang, L. E. Phillips, M. G. Caron, and W. C. Wetsel Vmat2 Heterozygous Mutant Mice Display a Depressive-Like Phenotype J. Neurosci., September 26, 2007; 27(39): 10520 - 10529. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Glatt, A. D. Wahner, D. J. White, A. Ruiz-Linares, and B. Ritz Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women Hum. Mol. Genet., January 15, 2006; 15(2): 299 - 305. [Abstract] [Full Text] [PDF] |
||||


